simvastatin

AssetSmall moleculeAlso MK0524B, Valsartan and simvastatin, valsartan + simvastatin, MK0653A

HMG-CoA reductase inhibitor and PPAR-alpha agonist combination regulating lipid metabolism.

Stage: Approved
Modality: Small molecule
Target: Lipid and ceramide metabolism
Indications: 34
Trials: 357
Developers: 5

Indications

34

Cerebrovascular disease
Approvedaccessdata.fda.gov7 Oct 2026
Coronary heart disease
Approvedaccessdata.fda.gov7 Oct 2026
Diabetes
Approvedaccessdata.fda.gov7 Oct 2026

31 more

Targets and what it contains4
Owner and partners5
Trials357
Evidence for its targets4
Competitors12
Aging relevance1
Signals9

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 39 sources